Skip to Main Content
April 02, 2021

Health Law Weekly

GAO: Federal Support for COVID-19 Drug Remdesivir Did Not Result in Federal Patent Rights

  • April 02, 2021

Although federal support for Gilead Sciences, Inc.’s (Gilead) COVID-19 drug remdesivir was substantial, it would not generate any federal patent rights in the drug, the Government Accountability Office (GAO) said in a March 31 report.

You must be logged in to access this content.